Cargando…

Effects of Stimulation of Soluble Guanylate Cyclase on Diabetic Nephropathy in Diabetic eNOS Knockout Mice on Top of Angiotensin II Receptor Blockade

The prevalence of diabetes mellitus and its complications, such as diabetic nephropathy (DN), is rising worldwide and prevention and treatment are therefore becoming increasingly important. Therapy of DN is particularly important for patients who do not adequately respond to angiotensin receptor blo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ott, Ina M., Alter, Markus L., von Websky, Karoline, Kretschmer, Axel, Tsuprykov, Oleg, Sharkovska, Yuliya, Krause-Relle, Katharina, Raila, Jens, Henze, Andrea, Stasch, Johannes-Peter, Hocher, Berthold
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3416804/ https://www.ncbi.nlm.nih.gov/pubmed/22900035 http://dx.doi.org/10.1371/journal.pone.0042623

Ejemplares similares

Additional stimulation of sGC on top of standard treatment with ARB`s may offer a new therapeutic approach for the treatment of diabetic nephropathy resistant to ARB treatment alone
por: Alter, Markus, et al.
Publicado: (2011)

Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl Rats
por: Geschka, Sandra, et al.
Publicado: (2011)

Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats
por: Hoffmann, Linda S., et al.
Publicado: (2015)

Chronic activation of heme free soluble guanylate cyclase leads to cardio-renal protection in experimental hypertension
por: Hoffmann, Linda S, et al.
Publicado: (2013)

Paternal eNOS deficiency in mice affects glucose homeostasis and liver glycogen in male offspring without inheritance of eNOS deficiency itself
por: Hocher, Berthold, et al.
Publicado: (2022)

Riociguat prevents fibrotic tissue remodelling and improves survival in salt-sensitive Dahl rats
por: Geschka, Sandra, et al.
Publicado: (2011)

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
por: von Websky, Karoline, et al.
Publicado: (2013)

Cardio-renal protection of riociguat (BAY 63-2521) in low- and high-renin models of hypertension
por: Kalk, Philipp, et al.
Publicado: (2009)

Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium
por: Chaykovska, Lyubov, et al.
Publicado: (2018)

Maternal eNOS deficiency determines a fatty liver phenotype of the offspring in a sex dependent manner
por: Hocher, Berthold, et al.
Publicado: (2016)

Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease
por: Bénardeau, Agnès, et al.
Publicado: (2021)

Podocyte VEGF-A Knockdown Induces Diffuse Glomerulosclerosis in Diabetic and in eNOS Knockout Mice
por: Veron, Delma, et al.
Publicado: (2022)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012)

Role of Endothelial Nitric Oxide Synthase in Diabetic Nephropathy: Lessons from Diabetic eNOS Knockout Mice
por: Takahashi, Takamune, et al.
Publicado: (2014)

Endothelial NO Production Is Mandatory for Epigallocatechin-3-Gallate–induced Vasodilation: Results From eNOS Knockout (eNOS(−/−)) Mice
por: Lorenz, Mario, et al.
Publicado: (2015)

Urinary Vitamin D Binding Protein and KIM-1 Are Potent New Biomarkers of Major Adverse Renal Events in Patients Undergoing Coronary Angiography
por: Chaykovska, Lyubov, et al.
Publicado: (2016)

Ameliorating diabetes-associated atherosclerosis and diabetic nephropathy through modulation of soluble guanylate cyclase
por: Sharma, Arpeeta, et al.
Publicado: (2023)

Fluorescence Dequenching Makes Haem-Free Soluble Guanylate Cyclase Detectable in Living Cells
por: Hoffmann, Linda S., et al.
Publicado: (2011)

Transthyretin Predicts Cardiovascular Outcome in Hemodialysis Patients With Type 2 Diabetes
por: Henze, Andrea, et al.
Publicado: (2012)

Structural studies of soluble guanylate cyclase
por: Macdonald, Jane, et al.
Publicado: (2009)

Nitric oxide-independent stimulation of soluble guanylate cyclase attenuates pulmonary fibrosis
por: Evgenov, Oleg V, et al.
Publicado: (2011)

Functional and Behavioral Restoration of Vision by Gene Therapy in the Guanylate Cyclase-1 (GC1) Knockout Mouse
por: Boye, Shannon E., et al.
Publicado: (2010)

Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice
por: Gangadharan Komala, Muralikrishna, et al.
Publicado: (2014)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

The uremic retention solute p-cresyl sulfate alters NO signal transduction by alteration of the soluble guanylate cyclase redox state
por: Meijers, Björn KI, et al.
Publicado: (2009)

Soluble Guanylate Cyclase Stimulators in Heart Failure
por: Kansakar, Sajog, et al.
Publicado: (2021)

eNOS 4a/b Polymorphism and Its Interaction with eNOS G894T Variants in Type 2 Diabetes Mellitus: Modifying the Risk of Diabetic Nephropathy
por: Rahimi, Zohreh, et al.
Publicado: (2013)

Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice
por: Thoonen, Robrecht, et al.
Publicado: (2015)

Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease
por: Cortese-Krott, Miriam M., et al.
Publicado: (2017)

Molecular mechanisms underlying pharmacological stimulation of eNOS expression and eNOS activity
por: Li, Huige, et al.
Publicado: (2009)

Effects of soluble guanylate cyclase stimulator on renal function in ZSF-1 model of diabetic nephropathy
por: Hu, Lufei, et al.
Publicado: (2022)

Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution
por: Balzer, Michael S., et al.
Publicado: (2023)

Pharmacological preconditioning with the guanylate cyclase activator cinaciguat (BAY 58-2667) protects against reperfusion injury after cardiopulmonary bypass
por: Radovits, Tamás, et al.
Publicado: (2009)

The discovery and characterization of novel soluble guanylate cyclase stimulators
por: Masferrer, Jaime L
Publicado: (2015)

Retrospection on the Role of Soluble Guanylate Cyclase in Parkinson's Disease
por: Ghanta, Mohankrishna, et al.
Publicado: (2017)

Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation
por: Wittenborn, Elizabeth C., et al.
Publicado: (2021)

The Soluble Guanylate Cyclase Activator BAY 58-2667 Protects against Morbidity and Mortality in Endotoxic Shock by Recoupling Organ Systems
por: Vandendriessche, Benjamin, et al.
Publicado: (2013)

The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
por: Vandendriessche, Benjamin, et al.
Publicado: (2013)

Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy
por: Chaykovska, Lyubov, et al.
Publicado: (2011)

Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteosomal degradation
por: Meurer, Sabine, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_qffccuc9i8tmj4qgi1ohace9hb